Abstract-The (pro)renin receptor [(P)RR] is implicated in organ pathology. We examined the cellular location of the (P)RR and whether a putative (P)RR antagonist, RILLKKMPSV, corresponding to the handle region of the prorenin prosegment (handle region peptide [HRP]) influences angiogenesis, inflammation, and neuronal and glial function in rat retina. The (P)RR was localized to retinal vessels, endothelial cells, and pericytes, but most immunolabeling was in ganglion cells and glia. HRP (1 mg/kg per day by IP injection) reduced physiological angiogenesis in developing retina. Moreover, HRP (0.1 mg/kg per day by subcutaneous minipump) reduced pathological retinal angiogenesis, inflammation, and vascular endothelial growth factor and intercellular adhesion molecule-1 mRNA in rats with oxygen-induced retinopathy (OIR) to an extent similar to valsartan (10 mg/kg per day, IP). In contrast to its effects on vasculature, HRP compromised the electroretinogram in shams and OIR and increased phosphorylated extracellular-signal-related protein kinase 1/2 immunolabeling in shams but not in OIR, whereas valsartan did not affect the electroretinogram and reduced extracellular-signal-related protein kinase 1/2 immunolabeling in OIR. Retinal (P)RR mRNA levels were increased in OIR; HRP, but not valsartan, increased (P)RR mRNA levels in shams, whereas both HRP and valsartan reduced (P)RR mRNA levels in OIR. A control peptide (VSPMKKLLIR, 0.1 mg/kg per day) did not influence retinal vasculopathy or function. Circulating HRP levels in rats administered 1 mg/kg per day HRP were undetectable (Ͻ3 pmol/L). We conclude that HRP had protective effects on the retinal vasculature similar to those of valsartan; however, unlike valsartan, HRP injured neuro-glia, which may involve the (P)RR, although the undetectable circulating HRP level makes a direct effect of HRP on retinal (P)RR function unlikely.
T he retina contains a local renin-angiotensin-aldosterone system, and angiotensin-converting enzyme and angiotensin type 1 receptor blockade (ARB) are known to improve pathology in ocular diseases such as retinopathy of prematurity and diabetic retinopathy. 1 A pathogenic role for prorenin in retina is suggested by its elevation in the plasma and vitreous of patients with diabetic retinopathy, 2 and plasma of patients with retinopathy of prematurity. 3 This idea has gained renewed interest since the cloning of the (pro)renin receptor [(P)RR]. 4 The current view is that the (P)RR acts in 2 different ways. 5, 6 First, the binding of prorenin to the (P)RR activates prorenin, resulting in the generation of angiotensin II. Second, prorenin binding to the (P)RR initiates cellular signaling mechanisms, such as mitogen-activated protein kinase, which, via phosphorylation of extracellular-signalrelated protein kinases (p-ERK) 1/2, results in cellular pathology that is independent of angiotensin II. To date, the role of the (P)RR in retinal disease is not understood. However, the finding of high (P)RR expression in the central nervous system, with associations with ocular development 7 and X-linked mental retardation and epilepsy, 8 suggests that it may influence retinal function. Also to be considered when interpreting the actions of (P)RR is that it may also function as an accessory protein of vacuolar-ATPase (v-ATPase). 9 A decoy-peptide epitope corresponding to amino acids 10 to 19 of the prorenin prosegment has been developed and termed the handle region peptide (HRP). 10, 11 It has been suggested that HRP prevents binding of renin and prorenin to the (P)RR inhibitor, 10, 11 and it has potent beneficial effects in diabetic glomerulosclerosis, 12 cardiac fibrosis, 13 and ocular pathology. 10, 11, 14 Despite these findings, there is ongoing debate about these effects of HRP and whether the (P)RR is involved. 5, 6, 15 Our goal was to evaluate the distribution of (P)RR in retina to gain insight into its cellular function and make a comprehensive evaluation of HRP's effects by studying angiogenesis, inflammation, and neuro-glial function in retinal development and a rat model of retinopathy of prematurity known as oxygen-induced retinopathy (OIR). Comparisons were made with the ARB valsartan.
Materials and Methods

Animals and Treatments
Procedures using Sprague-Dawley rats complied with the National Health and Medical Research Council of Australia's Guidelines for the care of animals in scientific research. HRP (sequence RILLKKMPSV) 12 and a control HRP peptide with the reverse sequence (VSPMKKLLIR, designated HRP-R) were syntheiszed by Invitrogen. Valsartan was obtained from Novartis Pharma.
Developing Retina
In rats, the retina develops postnatally, with most physiological angiogenesis occurring between birth and postnatal day (P) 7. Rat pups were administered either vehicle (0.9% NaCl) or 1 mg/kg HRP in 0.9% NaCl by daily IP injection from birth until P7. This dose and route of administration were based on a recent report in which plasma levels of HRP were measured. 10 Administration by osmotic minipump was not possible because of the small size of rat pups.
OIR
OIR represents a model of marked retinal pathology in response to changes in inspired oxygen that occurs between birth and P18. On P0, pups and their mothers were randomly assigned to the following groups: (1) sham, exposed to room air from birth until P18; (2) shamϩHRP; (3) shamϩvalsartan; (4) OIR control; (5) OIRϩHRP; (6) OIRϩvalsartan; and (7) OIRϩHRP-R. OIR was induced using a published method. 16 Pups were exposed from P0 until P11 to 80% oxygen for 22 hours/day and to room air for 2 hours/day, a process that suppresses normal retinal physiological angiogenesis. On P12, pups were placed in room air until P18, which causes the upregulation of angiogenic and inflammatory factors and pathological angiogenesis. OIR is also associated with deficits in neuronal and glial function. In OIR, treatments were given during the period of retinal pathology (P12 to P18). In shams, treatments were also given between P12 and P18. For comparability with most previous studies, HRP was delivered at 0.1 mg/kg per day via osmotic minipump (1007D, Alzet; in 0.9% saline at 0.5 L/hour in a 100-L volume), which was inserted into the flank. HRP-R was administered at 0.1 mg/kg per day by osmotic minipump (0.9% saline). Valsartan was given by IP injection (10 mg/kg per day in 0.1 mol/L Tris buffer). For detailed Materials and Methods, please see the Supplemental Data, available online at http://hyper.ahajournals.org.
Results
Body Weights
HRP, HRP-R, and valsartan had no effect on body weight (Supplemental Table I ).
(P)RR Localization
In retina, most (P)RR immunolabeling was apparent in ganglion cells and Müller cells in the inner nuclear layer (Figure 1 and Supplemental Figure I) . A glial site for (P)RR was confirmed in cultured rat glia (Figure 1 ). In retina, (P)RR immunolabeling was also identified in some retinal blood vessels, which was confirmed in cultured retinal endothelial cells and pericytes (Figure 1 ).
HRP Reduces Angiogenesis in Developing Retina and OIR
Developing Retina HRP reduced vascular growth from the optic disk to peripheral retina compared with untreated controls (Figure 2 ).
OIR
In OIR controls, blood vessel profiles were increased throughout the inner retina compared with sham controls, and they protruded into the vitreous. HRP and valsartan had no effect on the number of blood vessel profiles in the inner retina in shams, but they reduced blood vessel profiles to sham control levels in OIR, whereas HRP-R had no effect on retinal blood vessel profiles ( Figure 2 and Supplemental Figure II ).
HRP Reduces Inflammation in OIR
In shams, few leukocytes were detected in retinal vessels, and neither HRP nor valsartan influenced leukostasis (Figure 3) . Leukostasis was increased in OIR controls compared with sham groups, and it was reduced by both HRP and valsartan to sham levels, with no difference between treated groups. HRP-R had no effect on leukostasis (Figure 3 and Supplemental Figure II) . In shams, neither HRP nor valsartan affected retinal vascular endothelial growth factor (VEGF) or intercellular adhesion molecule-1 (ICAM-1) mRNA levels ( Figure 4 ). In OIR, both VEGF and ICAM-1 mRNA levels were increased compared with sham groups, and HRP and valsartan reduced these to sham control levels, whereas HRP-R had no effect on retinal VEGF or ICAM-1 mRNA levels in OIR.
(P)RR
In shams, HRP increased (P)RR mRNA, whereas valsartan had no effect. In OIR, (P)RR mRNA was increased compared with sham control, and both HRP and valsartan reduced (P)RR mRNA levels to those of the sham control, whereas HRP-R had no effect (Figure 4 ).
HRP Reduces Ganglion and Glial Cell Viability and Retinal Function
In sham controls, p-ERK1/2 immunolabeling was barely detected, and HRP caused a marked increase in p-ERK1/2 immunolabeling in ganglion cells and glia in the inner nuclear layer ( Figure 5 ). These findings with HRP treatment in shams were consistent with a decline in the electroretinogram (ERG). In particular, the postphotoreceptor responses of the b wave and the amacrine cell-derived oscillatory potentials were significantly reduced ( Figure 5 and Supplemental Figure III) . There was also a reduction in the photoreceptor response (a wave), indicating photoreceptor dysfunction in shams treated with HRP (Supplemental Figure III) . In contrast, valsartan had no effect on p-ERK1/2 or the ERG in shams ( Figure 5 ). In OIR controls, as expected, p-ERK1/2 was increased, and there was a decline in the ERG photoreceptor response (a wave) and postphotoreceptor responses (b wave, oscillatory potential amplitude), com- pared with sham controls ( Figure 5 and Supplemental Figure III ). In OIR, HRP had no significant effect on p-ERK1/2 immunolabeling and slightly reduced the ERG responses, whereas valsartan reduced p-ERK1/2 immunolabeling without effect on the ERG. HRP-R had no effect on either p-ERK1/2 immunolabeling or the ERG in OIR ( Figure 5 and Supplemental Figures II and III).
HRP Concentrations in Plasma and Blood
Plasma HRP concentrations were undetectable (Ͻ3 pmol/L) for rats infused with either 0.1 or 1 mg/kg HRP per day (Supplemental Figure IV) . We examined the metabolism of HRP in EDTA-plasma by high-performance liquid chromatography with monitoring of absorbance at 214 nm and found HRP to be degraded with a half-life of Ϸ5 minutes at 37°C, whereas it remained stable for at least 30 minutes at 0°C (data not shown). To exclude the possibility that plasma HRP levels were undetectable because of ex vivo metabolism, we measured HRP in blood collected directly into 4 mol/L guanidine thiocyanate to prevent HRP metabolism ex vivo. Consistent with the plasma HRP measurements, blood HRP concentrations were undetectable (Ͻ25 pmol/L) for rats infused with either 0.1 or 1 mg/kg HRP per day (Supplemental Figure IV ).
Discussion
Here we make the first report that the (P)RR is expressed on the retinal vasculature, neurons, and glia. Our evaluation of HRP in retina revealed distinct antiangiogenic and antiinflammatory effects that in OIR were comparable to ARB. Of particular interest was that in retinal neurons and glia where (P)RR was most abundantly expressed, HRP induced injury with increased p-ERK1/2 immunolabeling and a worsened ERG. HRP's ability to modulate (P)RR expression in retina Retinal VEGF, ICAM-1 and (P)RR mRNA at P18, determined by real-time polymerase chain reaction (fold change with respect to sham control). A, VEGF. B, ICAM-1. C, (P)RR. In shams, HRP and valsartan (Val) did not alter VEGF mRNA or ICAM-1 mRNA levels. In OIR, both VEGF mRNA and ICAM-1 mRNA were increased compared with shams. In OIR, HRP and Val reduced VEGF and ICAM-1 mRNA to sham controls. In shams, HRP increased (P)RR, whereas Val had no effect. In OIR controls, (P)RR was increased compared with sham controls. In OIR, both HRP and Val reduced (P)RR to sham control levels. In OIR, HRP-R had no effect on VEGF, ICAM-1, or (P)RR mRNA levels. Values are meanϮSEM; nϭ8 rats/group; *PϽ0.05 compared with sham control; †PϽ0.05 compared with OIR control.
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suggests that its actions involve the (P)RR through mechanisms yet to be defined. Our previous demonstration of prorenin on retinal blood vessels suggested a vascular role for prorenin. 17 However, the major location of prorenin was macroglial Müller cells, the site of renin expression. 18 Given that Müller cells contribute to retinal vasculopathy, it is possible that prorenin located in Müller cells has a paracrine effect on the vasculature. Here we report the localization of the (P)RR to retinal endothelial cells and pericytes, and also to glia in the inner nuclear layer, the site of Müller cell nuclei. Most notable was (P)RR immunolabeling in ganglion cells, which is consistent with reports of high levels of (P)RR expression in brain neurons. 19, 20 In contrast to our findings, a previous study reported both activated prorenin and (P)RR immunolabeling on retinal blood vessels, with no evidence of a neuro-glial localization. 14 We confirmed the previously reported antiinflammatory actions of HRP in OIR 14 and found HRP's actions to be similar to those of valsartan in OIR. In addition, we found HRP attenuated physiological angiogenesis in the developing retina to an extent similar to that previously reported for angiotensin-converting enzyme inhibition. 17 Our finding that neither HRP nor ARB had an effect on angiogenesis and inflammation in shams, yet reduced angiogenesis in developing retina at P7, is not surprising given that the retinal vasculature in shams at P12 is largely established and less vulnerable to antiangiogenic agents. 21 The finding that HRP-R did not alter vasculopathy in OIR further highlights the bioactive properties of HRP and suggests that the actions of HRP on the retina were sequence specific.
Retinal neurons and glia are damaged in OIR, which is reflected by a substantial reduction in retinal function as assessed by the ERG. 22 In retinal diseases such as diabetes, 23 ERK1/2 is activated in neurons and glia and acts as a stress sensor in cellular proliferation, differentiation, and repair. 24 One of our most interesting findings was in shams, where HRP markedly reduced the a and b waves and oscillatory potentials of the ERG and increased p-ERK1/2 expression in neurons and glia. This may suggest that in shams, although the vasculature was not influenced by HRP, neurons and glia were particularly sensitive to HRP. HRP also had a slight detrimental effect on the ERG in OIR despite the already heavily compromised ERG. p-ERK1/2 expression was nearmaximal in OIR, and therefore it is not surprising that there was no further increase with HRP. Given these findings and that retinal neuro-glia are immunolabeled for (P)RR, it is tempting to speculate that the detrimental effects of HRP were linked to the (P)RR. Our finding that HRP modulated retinal (P)RR mRNA levels in shams and OIR was suggestive of this possibility.
Our previous studies indicated that ARB prevents glial (astrocyte) apoptosis in OIR 25 and restores deficits in the ERG of diabetic animals. 26 Given these findings, it was not surprising that valsartan had no effect on the ERG and p-ERK1/2 in shams and improved p-ERK1/2 in OIR. It might be expected that valsartan would restore the ERG in OIR; however, this was unlikely given that although improvements in individual neuronal and glial cell populations can occur in OIR, recovery of overall retinal function can take much longer than the P18 time frame of the present study. 22 Overall, our findings highlight the injurious effects of HRP on retinal neurons and glia compared with ARB. Of interest was the reduction in retinal (P)RR mRNA by valsartan in In shams, HRP increased p-ERK1/2 (arrows) in the GCL and INL, whereas Val had no effect. In OIR control, p-ERK1/2 was increased compared with sham controls. In OIR, HRP had no effect on p-ERK1/2, whereas valsartan reduced immunolabeling. Top histogram shows meanϮSEM for p-ERK1/2 immunolabeling; nϭ5 to 7 rats/group; *PϽ0.05 compared with sham control, shamϩVal, and OIRϩVal. Bottom histogram shows meanϮSEM for peak-to-peak amplitude of the b wave of the ERG; nϭ5 to 12 rats/group; *PϽ0.05 compared with sham control; †PϽ0.05 compared with OIR control. In shams, HRP worsened the ERG, whereas Val had no effect. In OIR controls, the ERG was reduced compared with sham controls. In OIR, HRP slightly depressed the ERG, whereas Val had no effect. In OIR, HRP-R had no effect on p-ERK1/2 immunolabeling or ERG amplitude.
OIR, indicating a possible interaction between ARB and (P)RR expression in retinal disease. Our finding that the concentration of HRP in both plasma and blood was undetectable for rats infused with either 0.1 or 1 mg/kg HRP per day suggested rapid metabolism of the peptide in vivo, and this interpretation was supported by our finding that HRP was metabolized with a half-life of 5 minutes in EDTA-plasma at 37°C. Satofuka et al 10 reported transient plasma HRP concentrations of Ϸ100 nmol/L in mice administered 1 mg/kg HRP by IP injection. There are several possible reasons why we measured lower circulating HRP levels than reported by Satofuka et al 10 In contrast to the single IP injection of HRP by Satofuka et al, 10 we administered HRP by continuous subcutaneous infusion. HRP may have been absorbed into blood more rapidly and with less metabolism from the peritoneal cavity in their studies than from the subcutaneous space in our studies. It is also of note that the HRP assay used by Satofuka et al 10 measured immunoreactive HRP and may have detected HRP metabolites, whereas the high-performance liquid chromatographybased radioimmunoassay used in our study measured only intact HRP. We added plasma and blood to 4 mol/L guanidine thiocyanate before extraction to prevent any metabolism of HRP during sample processing. If HRP were in complex with the soluble (P)RR, 27 guanidine thiocyante would have dissociated the complex, thereby allowing HRP to be measured by our assay.
Several studies suggest that the effects of HRP are mediated by concentrations less than those required to influence prorenin binding to the (P)RR. Satofuka et al 10 found that 10 mol/L HRP produced only 50% inhibition of proreninstimulated ERK1/2 phosphorylation in brain-derived capillary endothelial cells. Although these authors reported peak plasma concentrations of Ϸ100 nmol/L in mice injected with 1 mg/kg IP, similar effects on retinopathy were seen with 0.1 mg/kg, and in another study, 0.01 mg/kg suppressed ocular inflammation. 11 Moreover, HRP administration at 1.8 to 3.6 g/kg per day by subcutaneous minipump prevented and reversed diabetic nephropathy in rats. 12, 28 The very low circulating concentration of HRP in our studies raises the question of its site of action in mediating its effects on the retina. Emerging evidence indicates that interleukins, complement, and circulating angiogenic cytokines are associated with retinopathy of prematurity. 29 One possibility is that HRP has actions in the subcutaneous tissue at the site of infusion, possibly modulating cytokine release or cells of the immune system. Overall, the present study raises important questions about the mechanisms by which HRP produces its effects, which may be particularly relevant to the retina.
In summary, we identified that HRP clearly exhibited antiangiogenic and antiinflammatory effects but also induced neuronal and glial injury in retina. Our findings that the (P)RR was expressed in retinal neurons and glia and that HRP modulated retinal (P)RR expression suggest that changes in (P)RR expression may mediate in part the effects of HRP on retinal function. This would be consistent with an emerging role for (P)RR in the central nervous system.
Perspectives
Of possible relevance to the actions of the (P)RR is its role as an accessory protein of v-ATPase. 6 v-ATPase is implicated in the stimulation of angiogenesis, inflammation, and neurotransmitter uptake. 9 Indeed, inhibition of v-ATPase with bafilomycin reduces these effects by inducing cellular autophagy. 9 Our results are consistent with HRP having similar actions to a v-ATPase inhibitor in retina. These properties of HRP and particularly its detrimental effects on neuro-glia may be confined to retinal development and OIR, and additional studies are required to determine whether HRP has a role in the treatment of ocular pathologies.
Animals
Procedures using Sprague Dawley rats complied with the National Health and Medical Research Council (NHMRC) of Australia's guidelines for the care of animals in scientific research. Sprague Dawley rats were obtained from the Animal Resources Centre (Perth, Western Australia). Prior to tissue collection, rats were anaesthetised with sodium pentobarbital (60mg/kg, Sigma-Aldrich, NSW, Australia).
Angiogenesis in Developing Retina
Retinae were dissected and fixed for 30 minutes in 4% paraformaldehyde (BDH Laboratory Supplies, Poole, England, UK) diluted in 0.1M phosphate buffered saline (PBS). Retinae were then permeabilised in 100% methanol for 10 minutes at 20 0 C and washed in 0.1M PBS containing 1% Triton X-100. They were subsequently incubated with the endothelial cell marker FITC Griffonia (Bandeiraea) Simplicifolia lectin B4 (Vector Laboratories, Burlingame, CA, USA), diluted 1:80 in 0.1M PBS containing 0.5% Triton X-100 (PBS/Triton X-100 solution), overnight at room temperature. This was followed by 6 x 15 minute washes with PBS/Triton X-100 solution. Retinae were then flat-mounted on to clean glass slides using fluorescent mounting medium (Dako NSW, Australia) and stored flat in the dark at 4ºC for one week. Wholemounts were viewed with fluorescence microscopy (Zeiss Axio Observer X1, Germany) and photographed at 100x magnification with a digital microscope camera (AxioCam MRc5 6.1.0.0, Carl Zeiss, Germany). Vessel length was measured from the optic disk to the edge of the vascular front in all 4 retinal quadrants and an average value was taken for each retina.
Angiogenesis in OIR
For OIR, eyes were fixed in 10% neutral buffered formalin, processed into paraffin and sectioned at 3µm. 1 In 6 randomly chosen sections (>60µm apart), 4 non-overlapping fields from each section were stained with Mayer's Haematoxylin and Eosin. Images were captured using Spot software (Diagnostic Instruments Inc., Missouri, USA) at x40 magnification. Blood vessel profiles were counted in the inner retina, which comprised the inner limiting membrane, ganglion cell layer and inner plexiform layer and blood vessels adherent to the retinal surface. A blood vessel profile was an endothelial cell or a blood vessel with a lumen. 1 
Retinal Leukostasis in OIR
Using a published method, rats in the OIR study were perfused via the left ventricle with 0.1M phosphate buffer saline (40mL) to remove non-adherent blood cells, and then rhodamine-coupled Concanavalin A lectin (25mg/kg; 4mL) to stain adherent leukocytes and the endothelium.
1 Non-overlapping images from the entire retina were captured at x200 magnification, and leukocytes counted per field of retina. 
Culture of Retinal Glia
Glia were isolated as described previously. 2 Briefly, retina were dissected from 10 Sprague Dawley rats and stored overnight at 4°C in DMEM supplemented with antibiotic/antimycotic. Retina were then disrupted with a sterile pipette, centrifuged at 1,000 rpm for 5 minutes, and the pellet re-suspended in DMEM/0.1% trypsin (Sigma)/70 IU collagenase I (Sigma) and incubated for 30 minutes at 37°C/5% CO 2 , with gentle agitation every 10 minutes. The digested retina was centrifuged at 1,000 rpm for 5 minutes. Cells were re-suspended in DMEM/10% FBS (Sigma)/antibiotic/antimycotic, and incubated at 37°C/5% CO 2 with media changes after 5 days, and 3-day changes thereafter. Cells displayed positive immunocytochemical staining for: glial fibrillary acidic protein (Dako, Vic, Australia), vimentin (Cymbus, Chandlers Ford, UK), glutamine synthetase (Chemicon, Vic, Australia), and S100b (Sigma).
Immunohistochemistry in Retina
Three-µm paraffin sections of retina were dewaxed, immersed in 3% H 2 O 2 for 15 minutes, washed in PBS and then incubated with 10% normal goat serum in PBS for 1 hour. For detection of (P)RR, a rabbit anti-human (P)RR antibody was applied overnight at 2 Briefly, in 4 nonoverlapping fields per section, Spot software was used to detect brown immunolabelling in the inner retina which comprised the inner limiting membrane, ganglion cell layer and inner plexiform layer. Results are expressed as immunolabelling per proportional field of inner retina.
Immunohistochemistry in Cultured Cells
Chamber slides (LabTek, Nunc, NY, USA) containing either cultured bovine retinal endothelial cells or bovine retinal pericytes (slides for endothelial cells coated with 0.1% fibronectin, Sigma), were washed with 0.1M PBS, and fixed with 4% paraformaldehyde in 0.1M PBS at 4°C for 30 minutes. Slides were washed with 0.1M PBS and permeabilized with 80% methanol/PBS at -20 °C for 15 minutes. After washing with 0.1M PBS, slides were blocked with 3% non-fat dry milk/1% bovine serum albumin in PBS for 30 minutes. Slides were washed with 0.1M PBS and incubated with 1:50 rabbit anti-human (P)RR in 0.1% bovine serum albumin/PBS for 1 hour. After washing with 0.1M PBS, slides were incubated with 1:200 goat anti-rabbit IgG-Alexa 568 (Invitrogen, Vic., Australia) in 0.1% BSA/PBS for 1 hour. Cells were counterstained with 300nM DAPI (Invitrogen) after washing with 0.1M PBS, re-washed, and coverslipped (Dako Fluorescent Mounting Medium). Images were captured using a Leica DC300 microscope interfaced with IM50 software (Leica). A noprimary negative control was included.
Retinal Function
Retinal neuronal and glial function in the OIR study were measured using the flash electroretinogram (ERG) at P18 as previously described. 
Real-time PCR and Agarose Gel Electrophoresis
Total RNA from retinae was isolated, subjected to DNase treatment and reverse transcribed as described previously.
1 Vascular endothelial growth factor (VEGF), intercellular adhesion molecule-1 (ICAM-1), 18S 1 and (P)RR were amplified and quantitative real-time PCR conducted.
1 Relative fold differences in gene expression relative to sham controls were calculating using the 2 -∆∆ method. Total RNA was harvested from glial cells using Trizol
Measurement of HRP in Plasma and Blood
The concentrations of HRP in plasma and blood were measured by HPLC-based radioimmunoassay, based on procedures established for the measurement of angiotensin and bradykinin peptides. 4 Antibody 102-285 was raised in a rabbit against acteylated peptide ArgIle-Leu-Leu-Lys-Lys-Met-Pro-Ser-Val-Tyr-Cys coupled via the C-terminus to keyhole limpet hemocyanin. The tracer for the radioimmunoassay was the same acetylated peptide with the cysteine residue carboxymethylated using iodoacetamide, then iodinated with 125 I, and the methionine residue oxidized with 1% hydrogen peroxide (30 min at 20°C) before purification by HPLC. Oxidation with hydrogen peroxide was performed to avoid the possibility of oxidized and non-oxidized peptides eluting at different positions on HPLC. The standard for the radioimmunoassay was acetylated and oxidized HRP, quantified by amino acid analysis. Antibody 102-285 at a dilution of 1/10,000 bound approximately 50% of tracer and the sensitivity of the radioimmunoassay was approximately 1 fmol/tube, with 50% displacement of tracer achieved with approximately 30 fmol/tube. The within and between assay coefficients of variation were 14% and 12%, respectively. HRP was measured in plasma and blood of female Sprague-Dawley rats (body weight 222±9 g, mean±SD, n=24) implanted with subcutaneous osmotic minipumps; 8 rats received vehicle (0.9% NaCl), 8 received 0.1 mg/kg per day HRP, and 8 received 1.0 mg/kg per day HRP. After 1 week of infusion, the rats were anesthetized with ketamine (75mg/kg) and xylazine (10mg/kg) by ip injection; 2 mL blood was collected from the inferior vena cava into a syringe containing 10 mL 4 mol/L guanidine thiocyanate (GTC), and blood was then collected from the aorta into tubes on ice containing EDTA, which were centrifuged and the plasma stored frozen at -80°C until assay.
For the measurement of plasma HRP levels, 0.5 mL plasma was added to 5 mL GTC, 1% trifluoroacetic acid (TFA), then extracted by C18 Sep-Pak cartridge (Waters Corporation, Milford, MA), acetylated and piperidine-treated, 3 and oxidized with 1% hydrogen peroxide before HPLC and radioimmunoassay of the HPLC fractions as described previously. 3 For the measurement of HRP in blood, blood collected into GTC was adjusted to 1% TFA, then extracted by C18 Sep-Pak, ether-extracted and processed as described for plasma. The recovery of 400 pmol/L HRP from plasma was 49.7±5.4% (mean±SD, n=8). HPLC fractions of plasma extracts from vehicle-infused rats had very little immunoreactivity (1-2 fmol/tube, Figure S3 ) and the lower limit of detection of HRP in plasma was approximately 3 pmol/L. The recovery of 100 pmol/L HRP from blood was 29.4±6.9% (mean±SD, n=8). HPLC fractions of blood extracts from vehicle-infused rats had 10-20 fmol/tube of immunoreactivity ( Figure S3 ) and the lower limit of detection of HRP in blood was approximately 25 pmol/L.
Statistics
Analyses were performed using either a one-way ANOVA (parametric) followed by appropriate post-hoc analyses correcting for the number of comparisons, or a Kruskal-Wallis test followed by individual Mann-Whitney U tests (non-parametric). Investigators were masked to the groups. expression of GFAP. 5 (P)RR immunolabelling is also apparent in ganglion cells (arrowhead). C. Section of retina from developing rat at postnatal day 7 showing labelling for (P)RR in the inner nuclear and ganglion cells (arrow). GCL, ganglion cell layer; ONL, outer nuclear layer. Scale bar=25µm. Figure S4 . Representative HRP immunoreactivity profiles (fmol/tube) for HPLC fractions of plasma and blood extracts. Acetylated, oxidized HRP eluted as a single peak in fractions 41-42. A. Extract of 0.5 mL plasma from vehicle-infused rat. B. Extract of 0.5 mL plasma from rat infused with HRP at 1.0 mg/kg per day. C. Extract of 0.5 mL plasma from control rat to which 200 fmol HRP was added before extraction. D. Extract of 2 mL blood from vehicleinfused rat. E. Extract of 2 mL blood from rat infused with HRP at 1.0 mg/kg per day. F. Extract of 2 mL blood from control rat to which 200 fmol HRP was added before extraction. All extracts were acteylated and oxidized before HPLC. For plasma extracts, 67% of the sample was injected onto the HPLC, whereas for blood extracts, 40% of the sample was injected onto the HPLC.
